Latest oral mucositis Stories
Treatment is being developed to reduce oral infection and pain associated with cancer treatments Honolulu, HI and Claremont CA (PRWEB) March 22, 2011 Biotech firm Synedgen announces the award of a competitive Phase II SBIR grant by the National Institutes of Health (NIH) to accelerate the development of Synedgenâ€™s proprietary oral disease treatments.
In the news release, NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002, issued 23-Mar-2011 by NephRx Corporation over PR Newswire, we are advised by the company that the original version should be disregarded. The complete, corrected release follows: NephRx Corp. Awarded U.S.
KALAMAZOO, Mich., March 23, 2011 /PRNewswire/ -- NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis.
DALLAS and NEW YORK, Oct. 15 /PRNewswire/ -- Access Pharmaceuticals, Inc.
DALLAS and NEW YORK, Oct. 11 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc.
KALAMAZOO, Mich., Oct. 7 /PRNewswire/ -- NephRx Corporation today announced that a new study has shown that its novel peptide NX002 demonstrated significant efficacy when tested in an animal model of oral mucositis.
DALLAS and NEW YORK, Sept. 15 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com.
DALLAS, and NEW YORK, Sept. 14 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC.
DALLAS and NEW YORK, July 20 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.
DALLAS and NEW YORK, June 24 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.
- A handkerchief.
- In general, any miraculous portrait of Christ.